How large is the cough hypersensitivity syndrome market, and what is its growth trajectory?
The cough hypersensitivity syndrome market size has grown strongly in recent years. It will grow from $10.36 billion in 2024 to $11.03 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increased awareness, telemedicine and remote monitoring, public health initiatives, research funding.
The cough hypersensitivity syndrome market size is expected to see strong growth in the next few years. It will grow to $14.65 billion in 2029 at a compound annual growth rate (CAGR) of 7.4%. The growth in the forecast period can be attributed to global health access, patient advocacy and support, quality of life improvements. Major trends in the forecast period include improved diagnosis and screening tools, personalized treatment approaches, new medications.
Get Your Free Sample of The Global Cough Hypersensitivity Syndrome Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12989&type=smp
Which major factors have contributed to the expansion of the cough hypersensitivity syndrome market?
The rising prevalence of chronic respiratory diseases is expected to propel the growth of the cough hypersensitivity syndrome market going forward. Chronic respiratory diseases (CRDs) refer to a group of long-term diseases that affect the airways and lungs, leading to persistent breathing difficulties and reduced lung function over time. Cough hypersensitivity syndrome treatment reduces discomfort, enhances respiratory health, thereby improving the quality of life for patients suffering from chronic respiratory diseases such as asthma. For instance, in June 2023, according to the Australian Institute of Health and Welfare, an Australia-based national agency, almost one-third (30%) of the Australian population, that is, 7.5 million people, are suffering from chronic respiratory diseases. Additionally, in May 2024, according to the data published by the National Center for Health Statistics (NCHS), a U.S.-based health statistics agency, the prevalence of current asthma among adults aged 18 and over in the United States increased from 8.4% in 2021 to 8.7% in 2022. Additionally, the incidence of asthma episodes in the past 12 months for adults in the same age group rose from 3.3% in 2021 to 3.7% in 2022. Therefore, the rising prevalence of chronic respiratory diseases drives the cough hypersensitivity syndrome market.
How is the cough hypersensitivity syndrome market segmented?
The cough hypersensitivity syndrome market covered in this report is segmented –
1) By Drug Class: Inhales Corticosteroids, Antitussive Agents, Short-acting Beta-2 Agonists, Anticholinergics, Proton Pump Inhibitors, Antihistamines, Other Drugs
2) By Route of Administration: Oral, Inhalation, Other Route Of Administration
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
Subsegments:
1) By Inhaled Corticosteroids: Budesonide, Fluticasone, Beclomethasone
2) By Antitussive Agents: Dextromethorphan, Codeine, Benzonatate
3) By Short-acting Beta-2 Agonists: Albuterol, Levalbuterol
4) By Anticholinergics: Ipratropium Bromide, Tiotropium
5) By Proton Pump Inhibitors: Omeprazole, Esomeprazole, Lansoprazole
6) By Antihistamines: Cetirizine, Loratadine, Diphenhydramine
7) By Other Drugs: Mucolytics, Combination Therapy Drugs
Order your report now for swift delivery
Who are the top competitors in the cough hypersensitivity syndrome market?
Major companies operating in the cough hypersensitivity syndrome market are Pfizer Inc., Johnson and Johnson Ltd., F. Hoffmann-La Roche AG, Bayer AG, Novartis AG, Merck and Co Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca Plc., GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim GmbH, Wyeth Pharmaceuticals Inc., AstraZeneca Pharmaceuticals LP, Teva Pharmaceutical Industries Ltd., Mylan N.V., Lupin Limited, Cadila Pharmaceuticals, Almirall S.A., Akorn Operating Company LLC, Kudco Ireland Ltd., Prestige Consumer Healthcare Inc., GMP Laboratories of America Inc., The Betty Mills Company, Acura Pharmaceuticals Inc.
Which key trends are expected to influence the cough hypersensitivity syndrome market in the coming years?
Major companies operating in the cough hypersensitivity syndrome market are focused on advancing asthma treatment pipelines such as asthma rescue inhalers to enhance patient outcomes and improve overall quality of life. Asthma rescue inhalers are portable devices delivering fast-acting medication to open airways quickly. It may help alleviate sudden coughing episodes by temporarily reducing airway sensitivity and providing relief from cough-related airway obstruction. For instance, in April 2024, Teva Pharmaceutical Industries Ltd., an Israel-based pharmaceutical company, partnered with Launch Therapeutics, a US-based clinical development company. This partnership aims to accelerate the clinical research program for its ICS-SABA (inhaled corticosteroid and short-acting beta-agonist) inhaler, TEV-‘248. This inhaler combines fluticasone propionate and albuterol sulfate, targeting both adult and pediatric asthma patients. Additionally, it aims to reduce reliance on generics.
Which regional trends are influencing the cough hypersensitivity syndrome market, and which area dominates the industry?
North America was the largest region in the cough hypersensitivity syndrome market in 2024. The regions covered in cough hypersensitivity syndrome market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
What Does The Cough Hypersensitivity Syndrome Market Report 2025 Offer?
The cough hypersensitivity syndrome market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Cough hypersensitivity syndrome (CHS) is a medical condition characterized by an exaggerated and abnormal response of the cough reflex to various stimuli, often leading to persistent and chronic coughing. It is commonly associated with conditions such as asthma, gastroesophageal reflux disease (GERD) and upper airway disorders.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12989
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
